Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free CRTX Stock Alerts

CRISM Therapeutics (CRTX) Competitors

GBX 9.70 +0.20 (+2.11%)
As of 09:56 AM Eastern
Compare

CRTX vs. GDP, KAV, RLD, BZT, and EMH

Should you buy CRISM Therapeutics stock or one of its competitors? MarketBeat compares CRISM Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CRISM Therapeutics include Goldplat (GDP), Kavango Resources (KAV), Richland Resources Ltd (RLD.L) (RLD), Bezant Resources (BZT), and European Metals (EMH). These companies are all part of the "metals & mining" industry.

How does CRISM Therapeutics compare to Goldplat?

Goldplat (LON:GDP) and CRISM Therapeutics (LON:CRTX) are both small-cap materials companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

1.8% of Goldplat shares are owned by institutional investors. Comparatively, 0.3% of CRISM Therapeutics shares are owned by institutional investors. 39.9% of Goldplat shares are owned by company insiders. Comparatively, 50.5% of CRISM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Goldplat had 1 more articles in the media than CRISM Therapeutics. MarketBeat recorded 1 mentions for Goldplat and 0 mentions for CRISM Therapeutics. Goldplat's average media sentiment score of 0.67 beat CRISM Therapeutics' score of 0.00 indicating that Goldplat is being referred to more favorably in the media.

Company Overall Sentiment
Goldplat Positive
CRISM Therapeutics Neutral

Goldplat has a net margin of 3.99% compared to CRISM Therapeutics' net margin of 0.00%. Goldplat's return on equity of 11.74% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Goldplat3.99% 11.74% 5.78%
CRISM Therapeutics N/A -139.63%-26.77%

Goldplat has higher revenue and earnings than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Goldplat, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Goldplat£72.22M0.40N/A£1.6810.12
CRISM Therapeutics£231K33.25-£792.20K-£5.10N/A

Goldplat has a beta of 0.091, meaning that its share price is 91% less volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.599, meaning that its share price is 40% less volatile than the broader market.

Summary

Goldplat beats CRISM Therapeutics on 9 of the 12 factors compared between the two stocks.

How does CRISM Therapeutics compare to Kavango Resources?

CRISM Therapeutics (LON:CRTX) and Kavango Resources (LON:KAV) are both small-cap materials companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

In the previous week, Kavango Resources had 1 more articles in the media than CRISM Therapeutics. MarketBeat recorded 1 mentions for Kavango Resources and 0 mentions for CRISM Therapeutics. CRISM Therapeutics' average media sentiment score of 0.00 equaled Kavango Resources'average media sentiment score.

Company Overall Sentiment
CRISM Therapeutics Neutral
Kavango Resources Neutral

Kavango Resources has higher revenue and earnings than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Kavango Resources, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£231K33.25-£792.20K-£5.10N/A
Kavango Resources£1.72M19.03-£5.48K-£0.48N/A

CRISM Therapeutics has a beta of 0.599, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Kavango Resources has a beta of 0.274, suggesting that its share price is 73% less volatile than the broader market.

CRISM Therapeutics has a net margin of 0.00% compared to Kavango Resources' net margin of -869.55%. Kavango Resources' return on equity of -68.85% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -139.63% -26.77%
Kavango Resources -869.55%-68.85%-14.06%

0.3% of CRISM Therapeutics shares are owned by institutional investors. 50.5% of CRISM Therapeutics shares are owned by company insiders. Comparatively, 8.7% of Kavango Resources shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Kavango Resources beats CRISM Therapeutics on 7 of the 12 factors compared between the two stocks.

How does CRISM Therapeutics compare to Richland Resources Ltd (RLD.L)?

Richland Resources Ltd (RLD.L) (LON:RLD) and CRISM Therapeutics (LON:CRTX) are both small-cap materials companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Richland Resources Ltd (RLD.L)'s return on equity of 0.00% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Richland Resources Ltd (RLD.L)N/A N/A N/A
CRISM Therapeutics N/A -139.63%-26.77%

0.3% of CRISM Therapeutics shares are owned by institutional investors. 50.5% of CRISM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Richland Resources Ltd (RLD.L) has higher earnings, but lower revenue than CRISM Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Richland Resources Ltd (RLD.L)£19K0.00N/AN/AN/A
CRISM Therapeutics£231K33.25-£792.20K-£5.10N/A

In the previous week, Richland Resources Ltd (RLD.L)'s average media sentiment score of 0.00 equaled CRISM Therapeutics'average media sentiment score.

Company Overall Sentiment
Richland Resources Ltd (RLD.L) Neutral
CRISM Therapeutics Neutral

Summary

CRISM Therapeutics beats Richland Resources Ltd (RLD.L) on 4 of the 6 factors compared between the two stocks.

How does CRISM Therapeutics compare to Bezant Resources?

Bezant Resources (LON:BZT) and CRISM Therapeutics (LON:CRTX) are both small-cap materials companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

In the previous week, Bezant Resources had 1 more articles in the media than CRISM Therapeutics. MarketBeat recorded 1 mentions for Bezant Resources and 0 mentions for CRISM Therapeutics. Bezant Resources' average media sentiment score of 0.81 beat CRISM Therapeutics' score of 0.00 indicating that Bezant Resources is being referred to more favorably in the media.

Company Overall Sentiment
Bezant Resources Positive
CRISM Therapeutics Neutral

Bezant Resources' return on equity of 21.18% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bezant ResourcesN/A 21.18% -41.17%
CRISM Therapeutics N/A -139.63%-26.77%

Bezant Resources has a beta of 0.852, meaning that its stock price is 15% less volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.599, meaning that its stock price is 40% less volatile than the broader market.

1.5% of Bezant Resources shares are held by institutional investors. Comparatively, 0.3% of CRISM Therapeutics shares are held by institutional investors. 7.3% of Bezant Resources shares are held by insiders. Comparatively, 50.5% of CRISM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Bezant Resources has higher earnings, but lower revenue than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Bezant Resources, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bezant ResourcesN/AN/A-£8.40K£0.0113.48
CRISM Therapeutics£231K33.25-£792.20K-£5.10N/A

Summary

Bezant Resources beats CRISM Therapeutics on 8 of the 11 factors compared between the two stocks.

How does CRISM Therapeutics compare to European Metals?

European Metals (LON:EMH) and CRISM Therapeutics (LON:CRTX) are both small-cap materials companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

CRISM Therapeutics has higher revenue and earnings than European Metals. European Metals is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
European MetalsN/AN/A-£2.30M-£3.81N/A
CRISM Therapeutics£231K33.25-£792.20K-£5.10N/A

In the previous week, European Metals had 2 more articles in the media than CRISM Therapeutics. MarketBeat recorded 2 mentions for European Metals and 0 mentions for CRISM Therapeutics. European Metals' average media sentiment score of 0.05 beat CRISM Therapeutics' score of 0.00 indicating that European Metals is being referred to more favorably in the media.

Company Overall Sentiment
European Metals Neutral
CRISM Therapeutics Neutral

European Metals has a beta of 0.329, meaning that its stock price is 67% less volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.599, meaning that its stock price is 40% less volatile than the broader market.

CRISM Therapeutics has a net margin of 0.00% compared to European Metals' net margin of -287.87%. European Metals' return on equity of -25.49% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
European Metals-287.87% -25.49% -2.47%
CRISM Therapeutics N/A -139.63%-26.77%

1.9% of European Metals shares are owned by institutional investors. Comparatively, 0.3% of CRISM Therapeutics shares are owned by institutional investors. 1.2% of European Metals shares are owned by insiders. Comparatively, 50.5% of CRISM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

European Metals and CRISM Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get CRISM Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRTX vs. The Competition

Export
MetricCRISM TherapeuticsMetals & Mining IndustryMaterials SectorLON Exchange
Market Cap£7.68M£3.75B£4.82B£2.86B
Dividend YieldN/A5.29%4.76%6.13%
P/E Ratio-1.9022.7721.13368.57
Price / Sales33.257,894.364,692.9883,546.77
Price / CashN/A28.9326.4727.89
Price / Book0.2310.428.787.14
Net Income-£792.20K£122.62M£155.10M£5.89B
7 Day Performance-2.02%6.07%5.08%1.00%
1 Month Performance-7.35%0.17%0.49%0.67%
1 Year Performance-10.10%51.45%41.27%74.90%

CRISM Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRTX
CRISM Therapeutics
N/AGBX 9.70
+2.1%		N/A-14.3%£7.68M£231KN/A4
GDP
Goldplat
N/AGBX 17.93
+1.0%		N/A+165.2%£29.89M£72.22M10.67458
KAV
Kavango Resources
N/AGBX 0.70
+3.7%		N/A-26.5%£29.47M£1.72MN/A43
RLD
Richland Resources Ltd (RLD.L)
N/AN/AN/AN/A£29.09M£19KN/A2,730
BZT
Bezant Resources
N/AGBX 0.13
-0.7%		N/A+185.7%£29.04MN/A15.065

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CRTX) was last updated on 8/5/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel